Nicholas RobbinsCherry - Midatech Pharma Finance Director, Director
| MTPDelisted Stock | USD 1.14 0.26 18.57% |
Director
Mr. Nicholas John RobbinsCherry, ACA, MBA is Finance Director, Director of Midatech Pharma PLC
| Age | 45 |
| Professional Marks | MBA |
| Phone | 44 29 2048 0180 |
| Web | https://www.midatechpharma.com |
Midatech Pharma Management Efficiency
The company has Return on Asset of (0.525) % which means that on every $100 spent on assets, it lost $0.525. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9547) %, meaning that it generated no profit with money invested by stockholders. Midatech Pharma's management efficiency ratios could be used to measure how well Midatech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Rodrigo Kirberg | Compania Cervecerias Unidas | 54 | |
| Xiaoguang Wu | 51Talk Online Education | 45 | |
| Gregoire Spoelberch | Anheuser Busch Inbev | 55 | |
| Kasper Rorsted | Anheuser Busch Inbev | 53 | |
| Manuel Eyzaguirre | Compania Cervecerias Unidas | N/A | |
| John McGloin | Perseus Mining Limited | N/A | |
| Olivier Goudet | Anheuser Busch Inbev | 54 | |
| Frank Lin | 51Talk Online Education | 55 | |
| Jorge Santos | Compania Cervecerias Unidas | N/A | |
| Didier Debrosse | Compania Cervecerias Unidas | 59 | |
| Alexandre Behring | Anheuser Busch Inbev | 51 | |
| Daniel Lougher | Perseus Mining Limited | 53 | |
| Gabriel Ventura | Anheuser Busch Inbev | N/A | |
| Martin Pompadur | Nexstar Broadcasting Group | 82 | |
| Dennis FitzSimons | Nexstar Broadcasting Group | 67 | |
| John Muse | Nexstar Broadcasting Group | 67 | |
| Anne Cooney | Summit Materials | 61 | |
| Rory Cullinan | Compania Cervecerias Unidas | 60 | |
| Wei Li | 51Talk Online Education | 41 | |
| Julia Kahr | Summit Materials | 37 | |
| Thomas McMillen | Nexstar Broadcasting Group | 65 | |
Management Performance
| Return On Equity | -0.95 | |||
| Return On Asset | -0.52 |
Midatech Pharma PLC Leadership Team
Elected by the shareholders, the Midatech Pharma's board of directors comprises two types of representatives: Midatech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Midatech. The board's role is to monitor Midatech Pharma's management team and ensure that shareholders' interests are well served. Midatech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Midatech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Craig Cook, COO / Chief Medical Officer | ||
| Stephen Stamp, CFO, CEO | ||
| Frederic Duchesne, Non-Executive Director | ||
| BSc MBIOL, Head Manufacturing | ||
| Tim Sparey, Chief Bus. Officer | ||
| David Benharris, Pres Inc | ||
| Fiona Sharp, Group Controller | ||
| Paul Protopapas, Non-Executive Director | ||
| Huaizheng Peng, Director | ||
| Dmitry MD, Chief Officer | ||
| Rolf Stahel, Non-Executive Chairman of the Board | ||
| Simon Turton, Senior Independent Non-executive Director | ||
| Nicholas RobbinsCherry, Finance Director, Director | ||
| Daniel MBA, VP Technology | ||
| Vincent Holmes, VP Operations | ||
| John Johnston, Non-Executive Director | ||
| Michele Luzi, Non-Executive Director | ||
| James Phillips, CEO, Director | ||
| Daniel Palmer, Chief Scientific Officer | ||
| Simon Vries, Non-Executive Director | ||
| Justin Barry, Head - Manufacturing |
Midatech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Midatech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.95 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (11.69) % | |||
| Current Valuation | (117.06 K) | |||
| Shares Outstanding | 6.93 M | |||
| Shares Owned By Institutions | 4.00 % | |||
| Number Of Shares Shorted | 84.86 K | |||
| Price To Earning | (1.02) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 5.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Midatech Stock
If you are still planning to invest in Midatech Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Midatech Pharma's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |